Introduction
The biogenic amines dopamine, serotonin, octopamine and tyramine can all be detected in C. elegans extracts by HPLC analysis and appear to function as neurotransmitters or neuromodulators Sanyal et al., 2004; Horvitz et al., 1982; Alkema et al., 2005) . Other signaling amines found in vertebrates (histamine, epinephrine, and norepinephrine) appear not to be made in C. elegans Sanyal et al., 2004 ). Biogenic amines modulate a variety of C. elegans behaviors including locomotion, egg laying (see Egg laying), defecation, and foraging. Dopamine and serotonin have established roles in mammalian nervous system function and abnormal signaling by these neurotransmitters has been implicated in several human diseases including Parkinson's disease, schizophrenia, and depression. It is not clear whether octopamine or its biosynthetic precursor tyramine function as neurotransmitters in mammals. Octopamine, however, can act as a neurotransmitter in invertebrates and recent evidence has implicated tyramine as a neurotransmitter in C. elegans . Studies in C. elegans have begun to elucidate the molecular and cellular signaling mechanisms by which these neurotransmitters control behavior.
A number of tools are available to study the molecular and cellular mechanisms of signaling by biogenic amines in C. elegans. The genes encoding the enzymes responsible for synthesis of these neurotransmitters and the gene encoding the transporter (cat-1) that loads these neurotransmitters into vesicles have been identified and mutants are available in each (see Figure 1) . Analysis of the phenotypes of such mutants has shed light on the behaviors controlled by the amines and detailed analysis of the expression patterns of the biosynthetic enzymes and transporter has helped identify the cells and neurons in which the neurotransmitters are made and released (see Table  1 ). Cells containing dopamine and serotonin can also be identified using formaldehyde-induced fluorescence and / or antibody stains. Seventeen putative biogenic amine receptors have been identified based on sequence similarity to mammalian receptors, and mutants for most of these are available (see Table 2 ). Although the specific biogenic amine that activates a given receptor homolog cannot be accurately predicted based purely on sequence analysis, in a growing number of cases pharmacological analysis of cloned C. elegans receptors has been used to determine their likely physiological ligands (see Table 2 ). Transgenes in which the promoters for the receptors drive expression of fluorescent proteins have been used to identify the cells in which the receptors are expressed and that thus respond to the neurotransmitter signal (see Table 2 ). Finally, a variety of drugs that target biogenic amine receptors are available and their effects on behavior can be helpful in determining the physiological roles of the receptors (see Table 3 ). The specificity of these drugs on C. elegans receptors is however largely unclear, as most of the drugs were developed against mammalian receptors and interact with regions of the receptors that may not be evolutionarily conserved. As a result, many of the drugs tested show different affinities for C. elegans receptors than seen for their mammalian receptor counterparts, and indeed may have completely different activities at the C. elegans receptors than they have at the mammalian receptors.
This chapter provides a reference source that organizes the growing body of literature in the field of biogenic amine signaling in C. elegans and also highlights current gaps in the field. 
Octopamine
Octopamine is synthesized from tyramine by the tyramine β-hydroxylase TBH-1. Based on the expression of TBH-1 as determined by antibody stain, octopamine synthesis is limited to the RIC interneurons and the gonadal sheath cells, . The behavioral defects of tbh-1 mutants have not been described in detail, however they share several (though apparently not all) pleiotropies with tdc-1 mutants (which cannot synthesize tyramine or octopamine, see Figure 1 ). One of the issues in this field is whether the cells that make octopamine also release tyramine as a neurotransmitter, or whether tyramine functions in those cells simply as a precursor in octopamine synthesis. While no octopamine receptors have yet been verified using pharmacological criteria, SER-3 Biogenic amine neurotransmitters in C. elegans appears to be a leading candidate and may be activated by octopamine in the SIA interneurons in response to starvation (Suo et al., 2006) . Behavioral defects associated with ser-3 mutants have not yet been described, however treatment of animals with exogenous octopamine causes several behavioral effects, including inhibition of egg laying and inhibition of pharyngeal pumping Alkema et al., 2005) . Both of these behaviors are normally stimulated by the presence of food, suggesting that octopamine signaling opposes the signal induced by food. Supporting the role of octopamine in the control of egg laying, treatment with phentolamine (an octopamine antagonist in insects) stimulates egg-laying behavior ).
Tyramine
Tyramine is present in low abundance in C. elegans, perhaps because it is made in only a few cells, and in some of those cells serves as an intermediate in the synthesis of octopamine . The enzyme used to synthesize tyramine (TDC-1) appears to be expressed in only two cells types that do not also express the enzyme that converts tyramine to octopamine (TBH-1), and these cells (the RIM-1 motorneurons and the uv1 neuroendocrine cells) may thus release tyramine as a neurotransmitter . tdc-1 mutants exhibit behavioral defects not shared with tbh-1 mutants, and characterization of these defects indicate that tyramine is required for the following: 1) inhibition of head oscillations as animals back in response to light touch to the anterior portion of the body; 2) inhibition of egg laying; and 3) modulation of spontaneous reversals Rex et al., 2004) . The latter two functions suggest that tyramine may be preferentially released during times of low food abundance when the animal needs to reduce egg laying and search for new food supplies. Two receptors, SER-2 and TYRA-2, have been identified that bind tyramine with relatively high affinity when expressed in cell culture Rex et al., 2004; Rex et al., 2005) . Mutations in ser-2 cause several behavioral defects (see Table 2 ), some of which are similar to the behavioral defects seen in tdc-1 mutants. For example, ser-2 mutants fail to suppress head oscillations in response to touch . Signaling to suppress head oscillations acts through the mechanosensory neurons ALM and AVM, which form gap junctions with the command interneurons AVA and AVD that control backward movement. The AVA and AVD neurons in turn form gap junctions with the tyraminergic RIM neurons which then synapse onto and presumably modulate the activity of the RMD motorneurons that directly innervate head muscles . Interestingly, none of the cells that have been identified that express SER-2 are postsynaptic to the RIM motorneurons, suggesting that if tyramine acts through SER-2 to suppress head oscillations it must function extrasynaptically. SER-2 is expressed on the head muscles that effect head movements, and thus these muscles are likely sites of action for tyramine . While a single tyra-2 mutant is available, an analysis of TYRA-2 effects on behavior has not yet been published. TYRA-2 is expressed in neurons of the amphid sensilla (ASE, ASG, ASH and ASI), the ALM mechanosensory neurons and a few other neurons (Rex et al., 2005) . The expression of TYRA-2 on the ALM neurons suggests that tyramine could inhibit head oscillations by modulating the activity of the ALM neurons, which in turn synapse onto and presumably modulate the activity of the RMD neurons. The ALM neurons are not postsynaptic to the neurons that make tyramine and thus tyramine would have to act extrasynaptically to act through ALM-expressed TYRA-2 receptors.
Exogenous tyramine inhibits serotonin-stimulated pharyngeal pumping, and mutations in ser-2 block this effect, consistent with the idea that tyramine is released in response to food deprivation to inhibit pharyngeal pumping. SER-2 is expressed on pharyngeal muscles and thus tyramine could act directly on them . Exogenous tyramine also inhibits egg laying in wild-type animals, and tdc-1 mutants are weakly hyperactive egg layers . If tyramine does inhibit egg laying it likely does not act through SER-2, as tyramine still inhibits egg laying in ser-2 mutants. While the synthesis of tyramine in the gonadal sheath cells is consistent with a role in egg laying, tyramine may simply be an intermediate in those cells in the synthesis of octopamine. Indeed, the inhibitory effects of exogenous tyramine on egg-laying behavior may be the result of tyramine being converted to octopamine inside the animal, as the effects of exogenous tyramine have not been tested in tbh-1 mutants, and exogenous octopamine also inhibits egg laying.
Biogenic amine neurotransmitters in C. elegans 
Dopamine
Dopamine is made in eight neurons in the hermaphrodite and in an additional six neurons located in the tail of the male (see Table 1 ). Each of these fourteen neurons are thought to be mechanosensory, and ablation of these cells or mutations that block synthesis or release of dopamine cause defects in the animal's ability to sense or respond to changes in its environment (see Mechanosensation , 1999) . Dopamine signaling has established roles in the modulation of locomotion behavior and in learning. Dopamine-dependent effects on C. elegans behavior have been gleaned primarily from the analysis of: 1) wild-type animals exposed to exogenous dopamine; 2) wild-type animals in which the dopaminergic neurons have been ablated; and 3) mutants for cat-2, which encodes a tyrosine hydroxylase responsible for catalyzing the rate-limiting step in the synthesis of dopamine (see Figure 1 Dopamine signaling allows C. elegans to respond to changes in its environment by modulating locomotion behavior. Well-fed, wild-type animals slow their locomotion rate when they encounter a bacterial lawn and this "basal slowing response" requires dopamine, as cat-2 mutants or animals in which the dopaminergic neurons have been ablated fail to exhibit basal slowing . Consistent with the idea that dopaminergic neurons are mechanosensory, this slowing response appears to be caused by physical rather than chemical attributes of the bacterial lawn as wild-type animals also slow in response to a Sephadex matrix and this slowing response also requires cat-2 (Sawin et al., 2000). Dopamine signaling also allows animals to search efficiently for new food sources. Well-fed, wild-type animals after exhausting a food source search the immediate area for additional food before expanding their search to include more distant, surrounding areas. This localized search for food is called area restricted searching and is accomplished in C. elegans through an increased frequency of high-angled turns immediately after an animal has exhausted a food supply. If, after a short time, the animal fails to find additional food in the area where it had been feeding, the frequency of high-angled turns is reduced and, as a result, the animal begins to explore more distant areas. Dopamine signaling is required for area restricted searching as cat-2 mutants or animals in which the dopaminergic neurons have been ablated do not increase the frequency of high-angled turns immediately after exhausting their food supply like wild-type animals and thus spend less time in the immediate area in which food was recently exhausted. Consistent with this role for dopamine signaling, animals exposed to exogenous dopamine display an increased frequency of high-angled turns and animals exposed to raclopride, a dopamine antagonist, display a decreased frequency of high-angled turns (Hills et al., 2004) . Dopamine thus plays at least two distinct roles in the modulation of locomotion behavior to ensure that animals remain in the area of food. This ability to stay near food is vital for C. elegans to survive in the wild, and animals that briefly wander off a food source must quickly relocate it. In such animals dopamine signals to cause an increased frequency of high-angled turns that prevent the animal from wandering too far from the food source. Upon re-encountering the food source dopamine signals to cause a slowing of forward locomotion increasing the likelihood that the animal does not wander away from the food source again. If however, the animal depletes the food source, the increased frequency of high-angled turns would cause the animal to search the local environment efficiently for new food. Upon failing to encounter new food in the local environment, the frequency of the high-angled turns diminishes and the animal then explores for more distant sources of food. Dopamine signaling also allows C. elegans to alter their behavior based upon previous experience. That is, dopamine affects learning in C. elegans. For example, wild-type animals respond to a nonlocalized mechanical stimulus (plate tapping) by either backing or by accelerating their forward locomotion rate (Rose and Rankin, 2001 ). Upon repeated tapping of the plate wild-type animals habituate to the stimulus and display a decreased frequency of reversals. Habituation to plate tapping is modulated by dopamine signaling as cat-2 mutants and mutants of the D1-like dopamine receptor dop-1 habituate to tap more rapidly than do wild-type animals. Additionally, normal tap response can be restored in cat-2 mutants by exposing them to exogenous dopamine . Interestingly dopamine does not control whether or not the animal can respond or habituate to tap as both wild-type Biogenic amine neurotransmitters in C. elegans and mutant animals respond to repeated tapping by reducing reversal rates to the same extent, rather dopamine affects how rapidly the animal responds to repeated tapping. DOP-1 is expressed in the mechanosensory neurons ALM and PLM (among others) and rescue experiments showed that dopamine acts through the DOP-1 receptor in the mechanosensory neurons to modulate the tap response . The molecular mechanisms used by dopamine to modulate habituation remain unclear but could certainly be limited to the modulation of the activity or the recovery from activation of the ALM and PLM neurons. Dopamine is also required for another form of learning, state-dependent olfactory adaptation (see Chemosensation in C. elegans). Animals exposed for prolonged periods to an odorant adapt to the odorant stimulus and exhibit a diminished response to the odorant upon reexposure. Such adaptation lasts for several hours (Colbert and Bargmann, 1995) . Wild-type animals adapted to an odorant while intoxicated by ethanol exhibit adaptation to the odorant only if ethanol is again present during reexposure. If such adapted animals are instead reexposed to the odorant in the absence of intoxicating concentrations of ethanol they respond to the odorant as if they had not been preexposed. Thus adaptation to the odorant is state-dependent. The ability to acquire state-dependent adaptation requires dopamine as cat-1 and cat-2 mutants adapted to an odorant in the presence of ethanol show adaptation regardless of whether ethanol is present during the testing period (Bettinger and McIntire, 2004 ). The signaling mechanisms through which dopamine effects state-dependent learning have not yet been identified.
Four dopamine receptors (DOP-1 through DOP-4) have been identified in C. elegans, including homologs of each of the two classes of dopamine receptor (D1-and D2-like) found in mammals (see Table 2 ). Mutants are available in each receptor and analysis of the receptor mutants has allowed assignment of particular receptors to the modulation of specific behaviors. For example, mutants in the D2-like dopamine receptor DOP-3 fail to slow in response to a bacterial lawn. Thus, DOP-3 is the receptor activated by dopamine in response to a bacterial lawn to slow locomotion rate. The slowing defect of dop-3 mutants is rescued by mutations in the D1-like receptor DOP-1 indicating that DOP-1 and DOP-3 antagonize each other to control the rate of locomotion in response to changing environmental stimuli ). In C. elegans then, as in mammals, D1-and D2-like receptors can function antagonistically to control behavior. The DOP-1 and DOP-3 receptors are coexpressed in the motor neurons of the ventral cord and function there to modulate locomotion rate. The ventral cord motor neurons are not postsynaptic to the dopaminergic neurons, and thus dopamine can function extrasynaptically in C. elegans. As mentioned earlier, mutations in the DOP-1 receptor also cause defects in the ability of animals to respond to mechanical stimulation (plate tapping). DOP-1 functions in the touch neurons to modulate this response, and these neurons are also not postsynaptic to the dopaminergic neurons.
Dopamine may control other behaviors in addition to those revealed by the analysis of cat-2 mutants, as cat-2 null mutants retain significant levels of dopamine ). In mammals, enzymes known as tyrosinases may be capable of converting tyrosine to L-DOPA to partially bypass the requirement for tyrosine hydroxylase (Rios et al., 1999) . Four putative tyrosinases (tyr-1 through tyr-4) have been identified in C. elegans. Elimination of all dopamine signaling may be possible by combining mutations in the tyrosinases with cat-2 mutations and the analysis of such mutants may reveal additional behaviors controlled by dopamine signaling not observed previously in the analysis of cat-2 mutants.
Serotonin
Serotonin is made in eight types of neurons in C. elegans (see Table 1 ). Its role in modulating behavior has been established largely through analysis of mutants for the genes encoding the serotonin biosynthetic enzymes, or through behavioral studies of wild-type animals exposed to drugs thought to alter serotonin signaling. Treatment with exogenous serotonin causes dramatic behavioral effects: it inhibits locomotion and the defecation motor program, but stimulates egg laying and pharyngeal pumping (Weinshenker et Serotonin signaling allows C. elegans to respond to changes in its environment by modulating locomotion behavior. Food-deprived animals slow their locomotion rate dramatically when they encounter a bacterial lawn and this "enhanced slowing response" requires serotonin as bas-1 and cat-4 mutants (but not cat-2 mutants) exhibit defects in enhanced slowing . Furthermore, treatment of bas-1; cat-4 double mutants with exogenous serotonin can rescue the enhanced slowing defects. The enhanced slowing response caused by serotonin signaling is much more dramatic than the slowing response caused by dopamine signaling, as many food-deprived animals come to a full stop as they encounter food whereas well-fed animals often simply slow their locomotion Biogenic amine neurotransmitters in C. elegans rate. Serotonin signaling thus provides a mechanism to ensure that food-deprived animals absolutely do not leave a food source once they have encountered it whereas dopamine signaling in well-fed animals encourages the animal to stay in the proximity of food but still may permit limited exploration for new or better food sources.
Serotonin is synthesized in the neurosecretory motor neurons (NSMs), which have sensory endings in the lumen of the pharynx that might sense food, and which also have access to the outside of the pharynx and the pseudocoelom, where serotonin might be released to communicate with the rest of the animal. Thus serotonergic neurons are well positioned to signal a favorable food environment and allow the animal to remain in the area of food to feed and to have progeny. Recently, a mutation was isolated in the tph-1 gene, which encodes another serotonin biosynthetic enzyme, tryptophan hydroxylase (see Figure 1) . tph-1 mutants show a modest reduction in egg laying and a reduction in the frequency of pharyngeal pumping, but have not yet been tested for defects in defecation or locomotion .
Four receptors have been identified that bind serotonin, including three G protein coupled (metabotropic) receptors (SER-1, SER-4 and SER-7) and one serotonin-gated chloride channel (MOD-1; Table 2 . A strong case has been made that HSN-released serotonin stimulates egg laying. Exogenous serotonin causes egg laying, and mutants in which the HSN neurons die (egl-1 mutants) are strongly egg-laying defective (Egl). Selective serotonin-reuptake inhibitors, which cause endogenous serotonin to persist in synapses after release, cause egg laying in wild-type animals but not in egl-1 mutants, suggesting the reuptake inhibitors potentiate the effects of HSN-released serotonin to stimulate egg laying. However, serotonin release is not solely responsible for the stimulation of egg laying, as mutations in the serotonin biosynthetic enzymes BAS-1 and CAT-4 do not cause animals to become Egl, and tph-1 mutants are only modestly defective in egg laying Sze et al., 2000) . Thus, other neurotransmitters released from the HSN neurons must function together with serotonin to stimulate egg laying. In addition to stimulating egg laying, serotonin is also thought to have an inhibitory effect on egg laying: calcium imaging studies suggest that serotonin autoreceptors inhibit HSN activity . One model is that serotonin release from the HSN stimulates a cluster of egg laying events, but also inhibits further HSN activity, explaining the~20 minute interval between clusters of egg-laying events that typically occurs . Inhibits locomotion 11, 3, 13 . Inhibits defecation 2, 11 .
Stimulates pharyngeal pumping 11, 3, 8, 6 (in the absence of food). Stimulates egg laying 2, 3, 7, 12 .
Causes male tail curling 4 . Causes reduced sensitivity to aldicarb-induced paralysis 21 . Stimulates vulval muscle calcium transients 22 .
Inhibits HSN calcium transients 22 . Inhibits olfactory adaptation 24 .
Octopamine Octopamine receptors Causes uncoordinated locomotion 3 . Inhibits pharyngeal pumping 3, 8, 6 (in the presence of food or 5-HT). Inhibits egg laying 3, 11 (in the presence of food or 5-HT). Inhibits defecation 2, 3 .
Tyramine Tyramine receptors SER-2 5 Inhibits egg laying (5, 9) (in the presence of food or 5-HT).
Quinpirole Dopamine receptors (agonist)
Inhibits locomotion 11 . Inhibits egg laying 11 .
Chlorpromazine D2 receptors (antagonist)
Stimulates egg laying 2 .
Raclopride Dopamine receptors (antagonist)
Blocks the effects of dopamine on turning frequency 25 . Eliminates area-restricted search behavior 25 α-methyl 5-HT Serotonin receptors (agonist) SER-1 29 Stimulates egg laying 23 .
Methiothepin Serotonin receptors (antagonist)
MOD-1 14 Blocks 5-HT-induced inhibition of locomotion 13 . Causes defects in enhanced slowing 13 . Causes hypersensitivity to aldicarb-induced paralysis 21 .
Mianserin Serotonin receptors (antagonist)
MOD-1 14 Blocks 5-HT-induced inhibition of locomotion 13 . Causes defects in enhanced slowing 13 .
Gramine Serotonin receptors (antagonist)
Inhibits pharyngeal pumping 8 .
Ketanserin Serotonin receptors (antagonist)
Causes hypersensitivity to aldicarb-induced paralysis 21 .
Fluoxetine Serotonin-specific reuptake transporter (inhibitor)
MOD-5 and others 16, 17, 26 Stimulates egg laying 2, 16 . Potentiates enhanced slowing response 13, 17 . Stimulates nose contraction16. Inhibits locomotion 16, 21 .
Paroxetine Serotonin-specific reuptake transporter (inhibitor)
Stimulates nose contraction 16 .
Clomipramine Serotonin reuptake transporter (inhibitor)
Stimulates egg laying 2 . Stimulates nose contraction 16 .
Imipramine
Monoamine reuptake transporter (inhibitor) EGL-2 18 Stimulates egg laying 2, 12, 19 . Stimulates pharyngeal pumping 20 .
Drug

Mammalian / invertebrate targets
C. elegans targets a Effects of drugs on wild-type C. elegans
Reserpine
Monoamine vesicular transporter (inhibitor)
Stimulates locomotion 15 (in the presence of food). Inhibits egg laying 15 .
Phentolamine
Octopamine and adrenergic receptors (antagonist)
Stimulates egg laying 3 .
a To qualify as a C. elegans target for a particular drug either: 1) mutation of the gene encoding the target protein must cause amine or drug-specific behavioral defects and lessen the behavioral effects of exogenous drug exposure; or 2) the target protein must bind to the drug in vitro and mutation of the gene encoding the target protein must lessen the effects of the exogenous drug in vivo.
